In this issue:
Guselkumab for moderate psoriasis with low BSA and high-impact site involvement
Real-world evidence on palmoplantar pustulosis
Biologics and synovitis and enthesitis associated with subclinical PsA
Tildrakizumab in psoriatic patients with current/past malignancy
Secukinumab for moderate-to-severe hidradenitis suppurativa
Conjunctivitis in atopic dermatitis treated with dupilumab or tralokinumab
Intralesional rituximab in recalcitrant oral and scalp pemphigus
Hepatic safety of IL-17 inhibitors in psoriasis and PsA
Therapeutic drug monitoring of adalimumab in hidradenitis suppurativa
Bimekizumab in patients with moderate-to-severe hidradenitis suppurativa
Please login below to download this issue (PDF)